Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2013-05-13 Regulatory Filings
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
U.S. FDA grants priority review to Simeprevir for combination treatment of genotype 1 chronic hepatitis C
Regulatory Filings Classification · 95% confidence The document is a press release dated May 13, 2013, announcing that the U.S. FDA has granted Priority Review to a New Drug Application (NDA) for the drug simeprevir for treating chronic hepatitis C. This announcement concerns a regulatory action (FDA review status) related to a pharmaceutical product. It is not a full Annual Report (10-K), an Interim Report (IR), an Earnings Release (ER), or a standard Audit Report (AR). Since it is a specific announcement regarding regulatory/legal progress concerning a drug application, it fits best under the general 'Regulatory Filings' category (RNS) as a specific regulatory update that doesn't map to the other specialized codes like DIRS, DIV, or CAP. Given the context of FDA action, RNS (Regulatory Filings) is the most appropriate general classification for this type of announcement when a more specific regulatory event code is not available.
2013-05-13 English
Resolutions at the annual general meeting in Medivir on 6 May 2013
AGM Information Classification · 99% confidence The document explicitly states in the title and body that it contains the 'Resolutions at the annual general meeting in Medivir on 6 May 2013'. It details decisions made regarding the election of the board, auditor, remuneration, authorization to issue new shares, and approval of financial statements. This content is characteristic of the formal outcomes and decisions made during an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R). The document length (6007 chars) is substantial enough to be the primary document, not just an announcement of it.
2013-05-06 English
Beslut vid årsstämma i Medivir den 6 maj 2013
AGM Information Classification · 99% confidence The document is explicitly titled "Beslut vid årsstämma i Medivir den 6 maj 2013" (Decisions at the Annual General Meeting in Medivir on May 6, 2013). It details resolutions passed regarding the election of the board and auditor, board remuneration, guidelines for executive compensation, authorization for share issuance, decisions on the nomination committee process, approval of the 2012 financial statements, and the proposed appropriation of profit. These topics are the core components of an Annual General Meeting (AGM) outcome announcement. Therefore, the appropriate classification is AGM Information (AGM-R).
2013-05-06 Swedish
Interim / Quarterly Report 2013
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for the period 1 January – 31 March 2013. It contains comprehensive financial statements (income statement), management commentary, and detailed business updates. It is not an announcement of a report, but the report itself, containing substantive financial data and analysis for a period shorter than a full fiscal year. Q1 2013
2013-05-06 Swedish
Interim / Quarterly Report 2013
Interim / Quarterly Report Classification · 100% confidence The document is explicitly titled 'Interim Report, 1 January – 31 March 2013' and contains comprehensive financial statements, including consolidated earnings trends, balance sheet data, and detailed management commentary on business performance and R&D activities for the first quarter. It is not a mere announcement or certification, but the full quarterly financial report itself. Q1 2013
2013-05-06 English
Webcast presentation of Simeprevir phase III clinical data
Report Publication Announcement Classification · 99% confidence The document is a press release dated May 3, 2013, announcing a webcast/podcast presentation by Janssen R&D Ireland and Johnson & Johnson to discuss clinical data for the drug simeprevir. It provides details on how to access the presentation (via a link to the Johnson & Johnson investor website) and includes background information on the drug and the disease. Since it is an announcement about a presentation/webcast intended for investors and interested parties regarding clinical data, it most closely aligns with an Investor Presentation (IP) or potentially a Call Transcript (CT) if the webcast were transcribed. However, since it is announcing the *presentation* itself, and the content is focused on clinical data and strategy discussion points (even if the actual presentation isn't included), 'Investor Presentation' (IP) is the most fitting category for the *subject matter* being discussed, even though the document itself is the announcement of the event. Given the options, and the focus on clinical data presentation for investors, IP is the best fit over a general Regulatory Filing (RNS). It is not a full earnings release (ER) or a formal report (10-K, IR).
2013-05-03 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.